Thelansis

 Pro-Opiomelanocortin (POMC) Deficiency, a rare condition, manifests as monogenic obesity with severe early-onset obesity, adrenal insufficiency, red hair, and pale skin due to mutations in the POMC gene. This gene encodes the proopiomelanocortin protein, expressed in skin components such as melanocytes, keratinocytes, and dermal microvascular endothelial cells. The inheritance pattern is autosomal recessive. Glucocorticoids, CRH, and ultraviolet radiation control POMC expression. It is a prohormone for adrenocorticotropic hormone (ACTH), a crucial player in the adrenocortical response to stress. Promoter methylation regulates POMC expression, while in ACTH-dependent Cushing's syndrome, the POMC gene is intrinsically activated. POMC consists of three segments: N-POMC (N-terminus), ACTH (middle), and β-LPH (C-terminus). Only about 50 cases of POMC deficiency have been documented in the medical literature.   Thelansis’s “Pro-Opiomelanocortin (POMC) Market Outlook, Epidemiolo...

  Pro-opiomelanocortin (POMC) deficiency is a form of monogenic obesity resulting in severe early-onset obesity, adrenal insufficiency, red hair and pale skin. POMC deficiency is caused by mutations in the POMC gene, which provides instructions for making the proopiomelanocortin protein. The condition is inherited in an autosomal recessive pattern POMC deficiency is rare; approximately 50 cases have been reported in the medical literature. Thelansis’s “Pro-Opiomelanocortin (POMC) Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Pro-Opiomelanocortin (POMC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of ...